Robotic Flexible Ureteroscopy: A Step-by-Step Guide to the ILY® Platform.

Int Braz J UrolJan 1, 2026
Case ReportUrology

Giovanni Scala Marchini, Gabriel K Jahchan Alves, Rodrigo Javier Sánchez Sepúlveda et al.

✦ AI-curated · Sources linked

Condensed from the publisher's abstract. An xxcode editorial summary of this publication has not been generated yet.

From the abstract

Robotic flexible ureteroscopy (rfURS) is emerging as an alternative to manual flexible ureteroscopy for the treatment of upper urinary tract stones. Contemporary guidelines and reviews describe its potential ergonomic and radiation-related advantages, as well as comparable surgical outcomes (1-5).

Reported results

Draping and docking times were 167 and 645 seconds, respectively. Robotic console time was 115 minutes, including 52 minutes of laser lithotripsy at 8 Hz and 1.2 J. Basket extraction was not required. Undocking was completed in 74 seconds, and total operative time was 130 minutes. No intraoperative complications or troubleshooting events occurred. Postoperative day-1 computed tomography confirmed stone-free status.

Authors' conclusions

rfURS using the ILY® platform was feasible, safe, and effective. A standardized step-by-step workflow may facilitate adoption, improve procedural consistency, and enhance surgeon ergonomics (12). rfURS represents a meaningful step toward autonomous surgery (13).

Source

PubMed · PMID 42623600

Published in Int Braz J Urol. The text above is extracted from the publisher's own abstract and has not been edited by xxcode. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Urology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.